Ep 1. Sep 26, 2026

Welcome to Biotech Catch-up. I’m Harry. This episode covers five major biotech news stories from September 21–25, 2026. 1. Viking reported that patients maintained much of their earlier weight loss on less frequent injections during a 12-week period. The next question is whether that result lasts in larger and longer studies. 2. Vertex reported reductions in a marker of kidney damage with inaxaplin. Its larger AMPLITUDE trial is the more important test ahead. 3. GRAIL received a favorable FDA advisory vote for Galleri. The recommendation matters, but the test has not received FDA premarket approval. 4. Johnson & Johnson reported positive Phase 3 results for Caplyta in bipolar mania. Caplyta is approved for other uses; this proposed use needs further evidence and regulatory review. 5. ADARx and Iambic added to the list of biotech companies testing the IPO market. Their filings tell us about financing plans, not whether their drugs will work.